Anti-Human CD284 (TLR4) PE

Grouped product items
Size	Price	Qty
25 tests	$210.00
100 tests	$475.00

Additional HTA125 Formats

Cat.No.	Format	Starting From
26911-60	PE	$ 210.00
26911-25	SAFIRE Purified	$ 410.00

Catalog Number : 26911-60

description

The HTA125 monoclonal antibody specifically reacts with human CD284, a 110kDA type I transmembrane signaling molecule known as the Toll-like Receptor 4 (TLR4). CD284 is an important molecule in the innate immunity response to bacterial lipoproteins. It is expressed by monocytes, macrophages, and endothelial cells. The HTA125 antibody can block Lipopolysaccharide-induced cytokine production and immunoprecipitate human TLR4.

Additional Information

Clone:	HTA125
Format:	PE
Applications:	FC
Reactivity:	Human
Isotype:	Mouse IgG2a, kappa
Research Interest:	Innate Immunity
Cell Type:	Macrophage / Monocyte
Application:	FC
Clone:	HTA125
Preparation:	The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:	Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:	Akashi, S., Ogata, H., Kirikae, F., Kirikae, T., Kawasaki, K., Nishijima, M., ... & Miyake, K. (2000). Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2. Biochemical and biophysical research communications, 268(1), 172-177. Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., & Kimoto, M. (1999). MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. The Journal of experimental medicine,189(11), 1777-1782. Mirlashari, M. R., & Lyberg, T. (2003). Expression and involvement of Toll-like receptors (TLR) 2, TLR4, and CD14 in monocyte TNF-alpha production induced by lipopolysaccharides from Neisseria meningitidis. Medical science monitor: international medical journal of experimental and clinical research, 9(8), BR316-24.